{"component": "definition", "props": {"groups": [{"samples": [{"hash": "3DxPmi0wTBi", "uri": "/contracts/3DxPmi0wTBi#reference-product", "label": "Group Enrollment Agreement", "score": 31.8563995361, "published": true}, {"hash": "figIMFmlpho", "uri": "/contracts/figIMFmlpho#reference-product", "label": "Group Health Insurance Certificate of Coverage", "score": 27.4175224304, "published": true}, {"hash": "2nipX0p8ghd", "uri": "/contracts/2nipX0p8ghd#reference-product", "label": "Agreement of Coverage", "score": 26.835729599, "published": true}], "size": 21, "snippet_links": [{"key": "prescription-drug", "type": "definition", "offset": [19, 36]}], "snippet": "means a biological Prescription Drug.", "hash": "19f9efc155008b8432cfe30c7be423ff", "id": 1}, {"samples": [{"hash": "6o87pc98tFh", "uri": "https://legislature.vermont.gov/Documents/2018/Docs/JOURNAL/sj180501.pdf", "label": "legislature.vermont.gov", "score": 9.1642713547, "published": false}, {"hash": "iXzz2ibKvRe", "uri": "https://legislature.vermont.gov/Documents/2018/Docs/CALENDAR/sc180426.pdf", "label": "legislature.vermont.gov", "score": 9.1560573578, "published": false}, {"hash": "8XHgcX5dHYR", "uri": "https://legislature.vermont.gov/Documents/2018/Docs/CALENDAR/sc180424.pdf", "label": "legislature.vermont.gov", "score": 9.1492128372, "published": false}], "size": 11, "snippet_links": [{"key": "pursuant-to", "type": "clause", "offset": [45, 56]}, {"key": "interchangeable-biological-product", "type": "definition", "offset": [94, 128]}, {"key": "the-us", "type": "clause", "offset": [146, 153]}, {"key": "food-and-drug-administration", "type": "definition", "offset": [155, 183]}], "snippet": "means the single biological product licensed pursuant to 42 U.S.C. \u00a7 262(a) against which the interchangeable biological product was evaluated by the U.S. Food and Drug Administration pursuant to 42 U.S.C. \u00a7 262(k).", "hash": "41cb4d6acb066fdcaf0b94d46211b931", "id": 2}, {"samples": [{"hash": "1622e0LoQzi", "uri": "https://legislature.vermont.gov/Documents/2018/Docs/BILLS/S-0092/S-0092%20As%20Passed%20by%20Both%20House%20and%20Senate%20Unofficial.pdf", "label": "legislature.vermont.gov", "score": 12.1926240921, "published": false}, {"hash": "3PG1XIcej85", "uri": "https://legislature.vermont.gov/Documents/2018/WorkGroups/House%20Health%20Care/Bills/S.92/S.92~Jennifer%20Carbee~Draft%20No.%201.4,%204-13-2018,%20Biologics%20and%20Rx%20drug%20sections~4-13-2018.pdf", "label": "legislature.vermont.gov", "score": 10.1550569534, "published": false}, {"hash": "44QIpQSRA3a", "uri": "https://legislature.vermont.gov/Documents/2018/WorkGroups/House%20Health%20Care/Bills/S.92/S.92~Jennifer%20Carbee~Draft%20No.%201.5,%204-13-2018~4-13-2018.pdf", "label": "legislature.vermont.gov", "score": 10.0535030365, "published": false}], "size": 8, "snippet_links": [{"key": "biological-product", "type": "definition", "offset": [17, 35]}], "snippet": "means the single biological product licensed", "hash": "d247a2013d5f8d1bfcfb3f3435117d1c", "id": 3}, {"samples": [{"hash": "2oiDfZgHsq1", "uri": "/contracts/2oiDfZgHsq1#reference-product", "label": "Asset Purchase Agreement (Brickell Biotech, Inc.)", "score": 33.3340187073, "published": true}, {"hash": "h3zNRAGkSnG", "uri": "/contracts/h3zNRAGkSnG#reference-product", "label": "Exclusive License Agreement (Brickell Biotech, Inc.)", "score": 33.0876121521, "published": true}, {"hash": "8UrcbKwIItv", "uri": "/contracts/8UrcbKwIItv#reference-product", "label": "License and Development Agreement (Brickell Biotech, Inc.)", "score": 32.6659812927, "published": true}], "size": 4, "snippet_links": [{"key": "the-definition-of", "type": "definition", "offset": [29, 46]}, {"key": "generic-product", "type": "definition", "offset": [47, 62]}], "snippet": "has the meaning set forth in the definition of Generic Product.", "hash": "312711d7b36387887abc2a6a81edd780", "id": 4}, {"samples": [{"hash": "hSZRo9r5WrS", "uri": "https://mgaleg.maryland.gov/2025RS/bills/hb/hb0529f.pdf", "label": "mgaleg.maryland.gov", "score": 17.8534984589, "published": false}, {"hash": "4P7JzFcZU1o", "uri": "https://mgaleg.maryland.gov/2025RS/bills/sb/sb0393F.pdf", "label": "mgaleg.maryland.gov", "score": 17.8453483582, "published": false}, {"hash": "3lT2aLydlsV", "uri": "https://arkleg.state.ar.us/Home/FTPDocument?path=/Assembly/Interim%20Study%20Proposal%20and%20Resolution/ISP-2025-016.pdf", "label": "arkleg.state.ar.us", "score": 17.3759765625, "published": false}], "size": 4, "snippet_links": [{"key": "biological-product", "type": "definition", "offset": [15, 33]}], "snippet": "means a single biological product", "hash": "0e4d61da81190fdfd6176fe7010dbf2c", "id": 5}, {"samples": [{"hash": "1D6dbowDGNM", "uri": "http://delcode.delaware.gov/sessionlaws/ga148/chp080.shtml", "label": "delcode.delaware.gov", "score": 10.1704311371, "published": false}, {"hash": "5dzldxulOgm", "uri": "https://legis.delaware.gov/SessionLaws/Chapter/GetPdfDocument?fileAttachmentId=354380", "label": "legis.delaware.gov", "score": 8.3734703064, "published": false}, {"hash": "bJ0MrPYyCIC", "uri": "https://delcode.delaware.gov/sessionlaws/ga148/chp080a.pdf", "label": "delcode.delaware.gov", "score": 4.7734427452, "published": false}], "size": 3, "snippet_links": [{"key": "food-and-drug-administration", "type": "definition", "offset": [42, 70]}, {"key": "pursuant-to", "type": "clause", "offset": [71, 82]}], "snippet": "means a product as defined by the Federal Food and Drug Administration pursuant to 42 U.S.C. \u00a7 262.", "hash": "400114e2799ebb2a0586c4c896c1257f", "id": 6}, {"samples": [{"hash": "hrhhfhQBYVK", "uri": "/contracts/hrhhfhQBYVK#reference-product", "label": "Collaboration and License Agreement (Revance Therapeutics, Inc.)", "score": 29.3504447937, "published": true}, {"hash": "hJ8OyJrmzP8", "uri": "https://d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/de1b8db4-3ee4-4784-8c60-30ca0c35af61.pdf", "label": "d18rn0p25nwr6d.cloudfront.net", "score": 12.1718006134, "published": false}, {"hash": "hrlKQKfXAnc", "uri": "https://investors.revance.com/static-files/db5b6cf3-7680-4547-9fdb-8d19788e8ceb", "label": "investors.revance.com", "score": 9.9952087402, "published": false}], "size": 3, "snippet_links": [{"key": "active-ingredient", "type": "definition", "offset": [88, 105]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [135, 153]}, {"key": "authority-of-the", "type": "clause", "offset": [167, 183]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [204, 228]}, {"key": "the-foregoing", "type": "clause", "offset": [277, 290]}, {"key": "the-function", "type": "definition", "offset": [335, 347]}, {"key": "therapeutic-activity", "type": "definition", "offset": [351, 371]}, {"key": "require-the", "type": "clause", "offset": [426, 437]}, {"key": "conduct-of", "type": "clause", "offset": [438, 448]}, {"key": "clinical-program", "type": "clause", "offset": [460, 476]}, {"key": "phase-iii", "type": "definition", "offset": [494, 503]}, {"key": "devices-for", "type": "definition", "offset": [690, 701]}, {"key": "delivery-of", "type": "clause", "offset": [702, 713]}, {"key": "trade-name", "type": "definition", "offset": [870, 880]}, {"key": "each-case", "type": "definition", "offset": [885, 894]}, {"key": "at-any-time", "type": "clause", "offset": [991, 1002]}, {"key": "during-the-term", "type": "clause", "offset": [1003, 1018]}, {"key": "for-clarity", "type": "clause", "offset": [1020, 1031]}, {"key": "the-definition-of", "type": "definition", "offset": [1033, 1050]}], "snippet": "means (a) the injectable product containing botulinum neurotoxin serotype A as its sole active ingredient as marketed and manufactured by or on behalf of or under the authority of the Innovator as BOTOX\u00ae as of the Effective Date, together with any and all (b) modifications to the foregoing product described in (a) that do not change the function or therapeutic activity (including safety, purity and potency) or that do not require the conduct of a new full clinical program (Phase I through Phase III), (c) additional strengths and concentrations of any such product described in (a) or (b) that do not require the conduct of a new full clinical program (Phase I through Phase III), (d) devices for delivery of any such product described in (a), (b) or (c) by injection, and (e) such products described in (a), (b), (c) or (d) marketed under a different trademark or trade name, in each case ((b)-(e)): marketed and manufactured by or on behalf of or under the authority of the Innovator at any time during the Term. For clarity, the definition of Reference Product expressly excludes [*].", "hash": "dc40eba9ed92ff62de82fc52eb10a2ff", "id": 7}, {"samples": [{"hash": "dRKjgJH94KA", "uri": "/contracts/dRKjgJH94KA#reference-product", "label": "Development and License Agreement (Pfenex Inc.)", "score": 30.3497600555, "published": true}, {"hash": "3hb9jfLcu4L", "uri": "/contracts/3hb9jfLcu4L#reference-product", "label": "Mena Development and License Agreement (Pfenex Inc.)", "score": 30.3497600555, "published": true}, {"hash": "gsSUXtigioZ", "uri": "/contracts/gsSUXtigioZ#reference-product", "label": "Development and License Agreement (Pfenex Inc.)", "score": 29.5995883942, "published": true}], "size": 3, "snippet_links": [{"key": "in-the-territory", "type": "clause", "offset": [54, 70]}], "snippet": "means Forteo\u00ae (teriparatide), as branded and approved in the Territory.", "hash": "79fa370c5e027e5659d3c46cb8c1b89e", "id": 8}, {"samples": [{"hash": "40XWKt62dPh", "uri": "/contracts/40XWKt62dPh#reference-product", "label": "Development and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "6Ht5Brkq63", "uri": "/contracts/6Ht5Brkq63#reference-product", "label": "Development and License Agreement (Pfenex Inc.)", "score": 26.3059539795, "published": true}, {"hash": "6eqCYPrtfFx", "uri": "/contracts/6eqCYPrtfFx#reference-product", "label": "Development and License Agreement (Pfenex Inc.)", "score": 26.2840518951, "published": true}], "size": 3, "snippet_links": [{"key": "as-approved", "type": "definition", "offset": [31, 42]}, {"key": "applicable-jurisdiction", "type": "definition", "offset": [50, 73]}], "snippet": "means Lucentis\u00ae (Ranibizumab), as approved in the applicable jurisdiction.", "hash": "9c2e730ff8cbe830d3e031a6bc5a9778", "id": 9}, {"samples": [{"hash": "eNviYdDP22Z", "uri": "/contracts/eNviYdDP22Z#reference-product", "label": "Master Product Development and Collaboration Agreement (Biosante Pharmaceuticals Inc)", "score": 24.0472278595, "published": true}, {"hash": "97YoCLrgCTY", "uri": "/contracts/97YoCLrgCTY#reference-product", "label": "Master Product Development and Collaboration Agreement (Biosante Pharmaceuticals Inc)", "score": 23.943189621, "published": true}], "size": 3, "snippet_links": [{"key": "the-product", "type": "definition", "offset": [6, 17]}, {"key": "product-exhibit", "type": "definition", "offset": [104, 119]}], "snippet": "means the product currently marketed and sold under the pharmaceutical brand identified in the Amending Product Exhibit.", "hash": "6080b250182f9c9cbd1c98c7de8f4cbe", "id": 10}], "next_curs": "Cl4SWGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjoLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIacmVmZXJlbmNlLXByb2R1Y3QjMDAwMDAwMGEMogECZW4YACAA", "definition": {"size": 109, "snippet": "means a biological Prescription Drug.", "title": "Reference Product", "id": "reference-product", "examples": ["In addition, upon written request of the IND Beneficiary, the IND Filing Party shall take all actions necessary to permit the IND Beneficiary to cross-reference such IND/IMPD (in its entirety) in its own Regulatory Materials (including any IND) for a product (including any Collaboration Product) that includes the same Building Block as the <strong>Reference Product</strong>.", "Pfenex has not out-licensed or otherwise granted rights to any Third Party under any Pfenex Technology with respect to Product or the <strong>Reference Product</strong>.", "From the Signing Date until the foregoing exclusive license expires, neither Wyeth nor any of its Affiliates will market, sell, distribute or manufacture any Authorized Generic Product of XR <strong>Reference Product</strong> (in any dosage strength), or license, grant a waiver or otherwise authorize or cause or allow any Third Party to do the same, for sale in the Territory.", "From the Signing Date until the Compound Patent Termination Date, neither Wyeth nor any of its Affiliates will market, sell, supply, distribute or manufacture any Authorized Generic Product of IR <strong>Reference Product</strong> (in any dosage strength), or license, grant a waiver or otherwise authorize or cause or allow any Third Party to do the same, for sale in the Territory.", "As between Wyeth and Teva, Wyeth shall be solely responsible for all product liability claims filed by any Third Party to the extent that they claim injury from the IR <strong>Reference Product</strong> or the XR <strong>Reference Product</strong> or any Authorized Generic Products manufactured, sold or distributed by Wyeth or its Affiliates or any of their licensees.", "Wyeth shall notify Teva reasonably in advance of listing any Patent Rights on the Orange Book for XR <strong>Reference Product</strong>.", "Wyeth shall notify Teva reasonably in advance of listing any Patent Rights on the Orange Book for IR <strong>Reference Product</strong>.", "For the sake of clarity and without limiting the foregoing, any IR Product tablet shall be of a different shape than is any tablet of the IR <strong>Reference Product</strong> as of the Signing Date, and such IR Product tablets and any XR Product capsules and the packaging therefor shall not bear any markings, trademarks, trade names or other trade dress that are confusingly similar to that used by Wyeth or any of its Affiliates for the IR <strong>Reference Product</strong> or the XR <strong>Reference Product</strong>.", "If, at any time during the Royalty Term, Biosimilar Competition exists in a given country with respect to a <strong>Reference Product</strong>, then the Pfizer Royalty Rate and Licensee Royalty Rate used to calculate royalties for such <strong>Reference Product</strong> in such country shall be reduced by [***] for so long as such Biosimilar Competition exists.", "With respect to each Transition Product ANDA, during the applicable Transition Period, Seller will continue to hold, and be the \u201cin-name-only\u201d owner, of the Transition Product ANDA for the sole purpose of obtaining marketing approval for the applicable Transition <strong>Reference Product</strong> in China."], "related": [["combination-product", "Combination Product", "Combination Product"], ["reference-price", "Reference Price", "Reference Price"], ["reference-biological-product", "Reference biological product", "Reference biological product"], ["reference-pricei", "Reference Pricei", "Reference Pricei"], ["combination-products", "Combination Products", "Combination Products"]], "related_snippets": [], "updated": "2026-03-07T04:27:53+00:00"}, "json": true, "cursor": ""}}